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Ostenil mini) and triamcinolone (TA; Volon A10) for treatment
of osteoarthritis (OA) of the carpometacarpal (CMC) joint of the
thumb in a 26-week, controlled, randomized, masked-observer
study.
Methods: Patients were treated with three intra-articular injec-
tions of either SH (n=28) or TA (n=28). Primary assessments
were pain according to VAS and extensive clinical and func-
tional parameters such as swelling, grip power and range of
motion. The population was analysed using one- and two-sided
Mann-Whitney (MW) estimators.
Results: Maximum pain relief occurred at 2-3 weeks for TA and
at week 26 for SH after the first intra-articular injection. At weeks
2-3 TA was significantly better than SH (MW: 0.3319 and 0.3063;
p=0.9827 and 0.9929). At week 26 a slight superiority of SH could
be observed (MW: 0.53; p=0.3624) and non-inferiority could be
proven. After 26 weeks lateral pinch power was significantly
better in the SH-group (MW: 0.6331; p=0.0226). In all, 88.0% of
patients treated with SH and 79.2% of the TA-group described
pain improvement after 26 weeks. No adverse events with causal
connection to the investigational products occurred.
Conclusions: We conclude that a single course of three SH in-
jections is effective in relieving pain and improving joint function in
patients with OA of the CMC joint of the thumb. Although in com-
parison with triamcinolone its effects are achieved more slowly,
the results indicate a superior long-lasting effect of hyaluronan at
6 months after end of treatment period.
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SUPPRESSION OF TNF-α, IL-1β, INOS, AND P38
EXPRESSION BY THE COMBINATION OF AVOCADO SOY
UNSAPONIFIABLES, GLUCOSAMINE, AND CHONDROITIN
SULFATE IN HUMAN MACROPHAGE-LIKE THP-1 CELLS
R.Y. Au, A.Y. Au, C.G. Frondoza
Nutramax Laboratories, Inc., Edgewood, MD
Purpose: The present study determines whether the combina-
tion of Avocado Soy Unsaponifiables (ASU), glucosamine (Glu),
and chondroitin sulfate (CS) was more effective in suppressing
pro-inflammatory gene expression than ASU alone, or Glu and
CS together.
Methods: Human monocyte/macrophage surrogate THP-1 cells
(5 x 105 cells) were incubated for 24 hrs at 37°C and 5% CO2
with: (i) control media alone, (ii) ASU (8.3 μg/ml; NMX1000TM-
ASU), (iii) Glu (15 mM; FCHG49®) and CS (20 μg/ml; TRH122®),
or with (iv) a combination of ASU (8.3 μg/ml), Glu (15mM), and
CS (20 μg/ml). All test materials were supplied by Nutramax
Laboratories, Inc., Edgewood, MD. The cells were then activated
with 20 ng/ml LPS for 1 hour. Total RNA was extracted and
subjected to RT-PCR analysis using primers specific to TNF-α,
IL-1β, iNOS, p38, and S14 as the housekeeping gene.
Results: Pre-treatment with the combination of ASU, Glu, and
CS profoundly suppressed the expression of TNF-α, IL-1β, and
iNOS by 50-80% in activated THP-1 cells. The combination
treatment reduced TNF-α and IL-1β expression to levels similar
to baseline non-activated controls and reduced iNOS expression
to levels lower than baseline non-activated levels. The inhibitory
effect of the combined preparation on TNF-α, IL-1β, and iNOS
expression is more profound than ASU alone, or Glu and CS
together. The inhibition of cytokine and iNOS expression is
associated with a profound suppression of p38 expression.
Conclusions: In the present study, we demonstrate that the
combination of ASU, Glu, and CS was more effective in sup-
pressing pro-inflammatory gene expression than ASU alone, or
Glu and CS together. The combined preparation suppressed
TNF-α, IL-1β, and iNOS expression by downregulating p38, a
key signal transduction molecule involved in inflammation. Our
present findings suggest the utility of the combination product
to alleviate pain and inflammation in OA patients who may not
clinically respond to Glu and CS alone.
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EFFECTS OF HEAT STIMULATION VIA MICROWAVE
APPLICATOR ON CARTILAGE METABOLISM AND HSP70
EXPRESSION IN RABBIT KNEE JOINT
K.A. Takahashi, H. Tonomura, Y. Arai, A. Inoue, K. Sakao,
M. Saito, T. Kubo
Graduate School of Medical Science, Kyoto Prefectural
University of Medicine, Kyoto, Japan
Purpose: Thermotherapy is widely used to conservatively treat
joint diseases such as osteoarthritis (OA). While heat stimulation
of joints increases pain threshold to alleviate pain, its effects
on the articular cartilage have not been clarified. In the present
study, heat stimulation was applied to rabbit knee joints to in-
vestigate the changes in expressions of heat shock protein 70
(HSP70) and cartilage matrix genes in the articular cartilage in
vivo.
Methods: Heat stimulation (0-80 W) was applied to the knee
joints of Japanese white rabbits for 20 min using a microwave
applicator (2.45-GHz). After 8-72 hrs, the articular cartilage was
removed from the knee joints and proteins and total RNA were
extracted. As controls, the knee joints without heat stimulation
were analyzed. Expression of HSP70 was confirmed by real-
time PCR and Western blotting. Expression of proteoglycan core
protein and type II collagen were quantified using real-time PCR
to assess cartilage matrix metabolism.
Results: Compared to controls, expression of HSP70 mRNA was
higher with not less than 40 W of heat stimulation in an intensity-
dependent manner. Expressions of proteoglycan core protein
and type II collagen mRNA were higher with not less than 20 W
of heat stimulation and peaked with 40 W. When quercetin was
used to block the increases in HSP70 expression, the expression
of proteoglycan core protein mRNA did not increase.
Conclusions: External heat stimulation increased expression of
HSP70 in the articular cartilage. This suggested that external
heat stimulation reached the articular cartilage. Heat stimulation
also increased expression of proteoglycan core protein and type
II collagen mRNA in the articular cartilage, indicating increased
cartilage metabolism. HSP70 might thus be involved in the in-
creased expression of proteoglycan core protein. With some
improvements, heat stimulation might be actively used to protect
the cartilage in OA.
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Purpose: A syncretic drug comprises two compounds that are
designed to act synergistically through multiple pathways to pro-
vide a novel therapeutic effect, which neither component can
achieve alone. The syncretic drug candidate CRx-102 comprises
dipyramidole and low dose prednisolone and is in clinical de-
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P306 – Table 1. Treatment effect CRx-102 vs placebo ITT
Mean baseline Adjusted mean change Treatment effect (95% CI) p-value
CRx-102 Placebo CRx-102 Placebo
AUSCAN pain 289.4 304.5 -70.9 -20.2 50.8 (8.1, 93.5) 0.010
AUSCAN physical 561.3 610.3 -73.2 -32.6 40.5 (-28.4, 109.5) 0.123
AUSCAN stiffness 61.1 64.5 -15.2 -7.7 7.5 (-1.7, 16.7) 0.054
Joint pain VAS 58.3 62.1 -18.6 -6.3 12.3 (3.0, 21.5) 0.005
Patient global VAS 58.0 62.3 -15.9 -4.2 11.7 (2.5, 20.8) 0.007
Tender joint count 10.5 10.4 -3.7 -2.5 1.2 (-1.0, 3.4) 0.136
Swollen joint count 5.8 5.2 -2.5 -1.5 1.0 (-0.4, 2.4) 0.086
velopment for the treatment of immuno-inflammatory diseases.
Dipyramidole has been shown to selectively amplify the anti-
inflammatory effects of the steroid, without recapitulating the
steroid toxicity. The purpose of this study was to examine the
efficacy and safety of CRx-102 in patients with HOA, dosed with
3 mg prednisolone and 200 mg dipramidole on days 1-7 and 3
mg prednisolone and 400 mg dipyridamole on days 8-42.
Methods: Patients with HOA were enrolled into this randomized
blinded placebo-controlled 42 days study. Eighty-three patients
were enrolled at four centers in Norway, and randomized equally
between placebo and treatment with CRx-102. The majority
(93%) of the patients was female, and the mean age was 60
years. To be eligible patients had to have more than one swollen
and tender joint, a Kellgren-Lawrence (K-L) score of 2 or more
on radiographs, and a score of at least 150 mm pain on the
5x100 mm=500 mm AUSCAN visual analogue scale (VAS). The
primary endpoint was a reduction in pain using the AUSCAN
pain subscale index at Day 42. We also recorded number of PIP,
DIP and CMC joints with tenderness/pain on motion (tender joint
count (TCJ) range (0-20)) and a similar count of joints with soft
tissue swelling (swollen joint count (SJC)). The treatment effect is
presented from ANCOVA analyses adjusted for baseline values
as the difference (with 95% confidence intervals) between the
mean changes from baseline to 42 days with an intention to treat
(ITT) approach where the last post-baseline observation was
carried forward (LOCF) to replace missing values. One-sided
p-values for the differences of least square means adjusted for
baseline are also presented. We also performed per-protocol
(completer) analyses with LOCF.
Results: CRx-102 was statiscally superior to placebo at 42
days for the following endpoints with the ITT analyses: AUSCAN
pain, joint pain VAS, and patient global VAS (Table 1). The
difference for AUSCAN stiffness was borderline significant. With
the completer analyses significant group differences were also
observed for TJC and SJC, and the AUSCAN function subscale
was borderline significant (p=0.08). The overall withdrawal rate
was 22 out of 83 enrolled patients (27%); 6/41 (15%) for placebo
and 16/42 (38%) for active drug. The most frequently reported
adverse event during the study was headache; 52% in the CRx-
102 group compared to 15% in the placebo group. This adverse
event was most frequent during the beginning of dosing, and in
most cases transient.
Conclusions: The novel syncretic drug CRx-102 demonstrated
efficacy in reducing pain in hand OA in this short term study, and
was generally well tolerated. Efficacy was also seen on other
endpoints, including joint counts.
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Purpose: Despite the publication of the European Ligue Against
Rheumatism recommendations for the management of knee and
hip OA, few is known with respect to the way rheumatologists
(RH) really treat their OA patients, and especially prescribe
Symptomatic-slow acting drug in OA (SySADOA), classified in
these guidelines as second line therapy.
Aim of this study: To describe therapeutic uses of French RH
in knee, hip or hand OA regarding SySADOA prescription.
Methods: Cross-sectional pharmaco-epidemiologic study using
a questionnaire. During the last French Congress of Rheumatol-
ogy 500 RH had to answer a questionnaire on their habits re-
garding the use of SySADOA in knee, hip or hand OA. Collected
data: doctor’s characteristics, site of OA treated by SySADOA
and reason for their prescription, co-prescriptions, treatment du-
ration, treatment modality, dosage and route of administration.
Statistics: descriptive: numbers (%) and mean (SD).
Results: 392 rheumatologists answered the questionnaire, of
whom 38% had a private practice, 58% exercised in both hos-
pital and private setting, and 4% only in hospital. They were
aged 47 years, 37% were women, representative of all areas of
France. OA location for which SySADOA is prescribed are (fre-
quency of citations): Knee OA (95%), hip OA (84%), hand OA
including thumb base (66%), and generalized OA (49%). Spine
OA come after in citations. When is the decision taken? When
OA symptoms flare, in association with an NSAID (87%) and/or
a level 1 analgesic (75%). Level 2 analgesics are less associated
(37%). Intra-articular (IA) steroids are associated to SySADOA
in 45% of cases. As co-treatments, weight loss is cited by 65%,
braces by 62% and crutches by 54%. IA hyaluronans injections
are used by 55%, even initiated during a flare. As a long-term
treatment when symptoms are persistent, 97% use SySADOA:
85% in association with a level 1 analgesic. 57% say they often
associate with NSAIDs. 65% then use IA hyaluronans and 83%
prescribe physical therapy. Mean SySADOA treatment duration
reported is 3.8 (4.1) years. For 70% of RH, SySADOA are pre-
scribed more than 3 months, according to a continuous fashion
by 64%, intermit courses for 42%. In this sample, intermittent pre-
scription leaded to an average of 165 (74) days of treatment/year
and 2.4 courses/year (71.5 (37.4) days/course).
Conclusions: In this sample of 392 French RH, SySADOA
appear to be used either during a flare or to treat persistent
chronical symptoms. SySADOA are mostly associated with level
1 analgesics or NSAIDs. Non pharmacological treatments are
less associated. The durations of treatment (administered either
continuously or by course) are very long.
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